Mechanisms in cutaneous drug hypersensitivity reactions

Dermatotoxicology, Eighth Edition

Volumn , Issue , 2012, Pages 78-92

  Gonçalo, Margarida ^a   Bruynzeel, Derk P ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883324288     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (119)

1. Roujeau J. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-9.
2. Demoly P, Viola M, Gomes E, Romano A. Epidemiology and causes of drug hypersensitivity. In: Pichler WJ, eds. Drug Hypersensitivity. Basel: Karger, 2007: 2-17.
3. Fernandes B, Brites M, Gonçalo M, Figueiredo A. Farmacovigilância no Serviço de Dermatologia dos HUC no ano de 1998: estudo comparativo com 1988. Trab Soc Port Dermatol Venereol 2000; 58: 335-44.
4. Mockenhaupt M. Epidemiology and causes of severe cutaneous adverse reactions to drugs. In: Pichler WJ, eds. Drug Hypersensitivity. Basel: Karger, 2007: 18-31.
5. Santiago F, Gonçalo M, Reis J, Figueiredo A. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients. An Bras Dermatol 2011; 186: 483-9.
6. Friedmann P. Mechanisms in cutaneous drug hypersensitivity. Clin Exp Allergy 2003; 33: 861-72.
7. Pirmohamed M, Friedmann P, Molokhia M, et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 2011; 89: 896-901.
8. Caubet J-C, Pichler W, Eingenmann P. Educational case series:mechanisms of drug allergy. Pediatr Allergy Immunol 2011; 22:559-67.
9. Phillips E, Chung W-H, Mockenhaupt M, Roujeau J, Mallal S. Drug hypersensitivity; pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011; 127: S60-6.
10. Pichler W. Drug hypersensitivity reactions: classification and relationship to T-cell activation. In: Pichler WJ, eds. Drug Hypersensitivity. Basel: Karger, 2007: 168-89.
11. Lerch M, Pichler W. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol 2004; 4: 411-19.
12. Coelho S, Tellechea O, Reis J, Mariano A, Figueiredo A. Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Int J Dermatol 2006; 45: 995-6.
13. Allanore L, Roujeau J. Clinic and pathogenesis of severe bullous skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis. In:Pichler WJ, eds. Drug Hypersensitivity. Basel: Karger, 2007: 267-77.
14. Farhi D, Viguier M, Cosnes A, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology 2006; 212: 59-65.
15. Dam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta Derm Venereol 2008; 88: 87-9.
16. Torres M, Mayorga C, Blanca M. Urticaria and anaphylaxis due to betalactams (penicillins and cephalosporins). In: Pichler WJ, eds. Drug Hypersensitivity. Basel: Karger, 2007: 190-203.
17. Blanca M, Cornejo-Garcia J, Torres M, Mayorga C. Specificities of B cell reactions to drugs. The penicillin model. Toxicology 2005; 209: 181-4.
18. Bircher A. Drug-induced urticaria and angioedema caused by non-IgE mediated pathomechanisms. Eur J Dermatol 1999; 9: 657-63.
19. Blanca M, Romano A, Torres M, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64: 183-93.
20. Kvedariene V, Martins P, Rouanet L, Demoly P. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Clin Exp Allergy 2006; 36: 1072-7.
21. Ebo D, Leysen J, Mayorga C, et al. The in vitro diagnosis of drug allergy: status and perspectives. Allergy 2011; 66: 1275-86.
22. Demoly P. Anaphylatic reactions: value of skin and provocation tests. Toxicology 2005; 209: 221-3.
23. Brockow K. Contrast media hypersensitivity: scope of the problem. Toxicology 2005; 206: 189-92.
24. Mastalerz L, Setkowicz M, Szczeklik A. Mechanism of chronic urticaria exacerbation by aspirin. Curr Allergy Asthma Rep 2005; 5:277-83.
25. Blanca M, Thong B-H. Allergic drug reactions: from basic research to clinical practices. Curr Opin Allergy Clin Immunol 2011; 11: 275-8.
26. Grattan C. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003; 28: 123.
27. Lammintausta K, KorteKangas-Savolainen O. Oral challenge in suspected cutaneous adverse drug reactions. Acta Derm Venereol 2005; 85: 491-6.
28. Brönnimann M, Yawalkar N. Histopathology of drug-induced exanthems:is there a role in diagnosis of drug allergy? Curr Opin Allergy Clin Immunol 2005; 5: 317-21.
29. Barbaud A, Gonçalo M, Bircher A, Bruynzeel D. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45: 321-8.
30. Lammintausta K, KorteKangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005; 152:968-74.
31. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209: 209-16.
32. Gonçalo M, Bruynzeel D. Patch testing in drug eruptions. In:Johanssen J-D, Frosch P, Lepoitevin J-P, eds. Contact Dermatitis. 5th ed. Berlin-Heidelberg: Springer-Verlag, 2011: 475-92.
33. Britschgi M, Steiner U, Schmid S, et al. T-cell involvement in druginduced acute generalized exanthematic pustulosis. J Clin Invest 2001; 107: 1433-41.
34. Schaerli P, Britschgi M, Keller M, et al. Characterization of human T cells that regulate neutrophilic inflammation. J Immunol 2004; 173: 2151-8.
35. Gonçalo M, Serra D, Cabral A, Reis J, Tellechea O. Histopathology of positive skin tests in different drug eruptions. Invest Dermatol 2011; S33: 131.
36. Rozières A, Hennino A, Rodet K, et al. Detection and quantification of drug-specific T cells in penicillin allergy. Allergy 2009; 64: 534-42.
37. Yawalkar N, Hari Y, Frutig K, et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000; 115: 647-52.
38. Kuechler P, Britschgi M, Schmid S, et al. Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 2004; 59:613-22.
39. Rozières A, Vocanson M, Rodet K, et al. CD8T cells mediate skin allergy to amoxicillin in a mouse model. Allergy 2010; 65: 996-1003.
40. Pichler W, Naisbitt D, Park B. Immune pathomechanisms of drug hypersensitivity reactions. J Allergy Clin Immunol 2011; 127: S74-81.
41. Yawalkar N. Drug-induced exanthems. Toxicology 2005; 209: 131-4.
42. Schlapbach C, Zadowdniak A, Adam A, et al. NKp46cells express granulysin in multiple cutaneous adverse drug eruptions. Allergy 2011; 66: 1469-76.
43. Shiohara T, Takahashi R, Kano Y. Drug-induced hypersensitivity syndrome and viral reactivation. In: Pichler WJ, eds. Drug Hypersensitivity. Basel: Karger, 2007: 251-66.
44. Kardaun S, Sidoroff A, Valleyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609-12.
45. Santiago F, Gonçalo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in the diagnosis of drug hypersensitivity syndrome (DRESS). Contact Dermatitis 2010; 62: 47-53.
46. Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpes virus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004; 140: 183-8.
47. Hirahara K, Kano Y, Mitsuyama Y, et al. Differences in immunologicals alterations and underlying viral infections in two well-defined severe drug eruptions. Clin Exp Dermatol 2010; 35: 863-8.
48. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009; 13: 1-9.
49. Naisbitt D. Drug hypersensitivity reactions in the skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 2004; 194: 179-96.
50. Walsh S, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical picture and review of current finding. Clin Exp Dermatol 2010; 36: 6-11.
51. Sidoroff A, Halevy S, Bavinck J, Vaillant L, Roujeau J. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-19.
52. Britschgi M, Pichler W. Acute generalized exanthematous pustulosis. Role of cytotoxic T cells in pustule formation: a clue to neutrophil-mediated processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002; 2: 325-31.
53. Halevy S, Kardaun S, Daividovici B, Wechsler J. EuroSCAR and RegiSCAR study group. The spectrum of histopathological features in acute generalized exanthematous pusutulosis: a study of 102 cases. Br J Dermatol 2010; 163: 1245-52.
54. Serra D, Gonçalo M, Mariano A, Figueiredo A. Pustular psoriasis and drug-induced pustulosis. G Ital Dermatol Venerol 2011; 146:155-8.
55. Roujeau J, Bricard G, Nicolas J-F. Drug-induced epidermal necrolysis:important new pieces to end the puzzle. J Allergy Clin Immunol 2011; 128: 1277-8.
56. Quinn A, Brown K, Bonish B, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol 2005; 141: 683-7.
57. Faye O, Wechsler J, Roujeau J. Cell-mediated immunologic mechanism and severity of TEN. Arch Dermatol 2005; 141: 775-6.
58. Correia O, Delgado L, Ramos J, Resende C, Torrinha J. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8lymphocyte involvement. Arch Dermatol 1993; 129:466-8.
59. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis:effector cells are drug specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-15.
60. Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2002; 2: 317-23.
61. Gonçalo M, Oliveira H, Fernandes B, Robalo-Cordeiro M, Figueiredo A. Topical provocation in fixed drug eruption from nonsteroidal anti-inflammatory drugs. Exog Dermatol 2002; 1: 81-6.
62. Andrade P, Brinca A, Gonçalo M. Patch testing in fixed drug eruptions-a 20-year review. Contact Dermatitis 2011; 65: 195-201.
63. Vocanson M, Hennino A, Rozières A, Poyet G, Nicolas J-F. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 2009; 64: 1699-714.
64. Hausermann P, Harr T, Bircher A. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51: 297-310.
65. Winnicki M, Shear N. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol 2011; 12: 171-80.
66. Veien N. Systemic contact dermatitis. Int J Dermatol 2011; 50:1445-56.
67. Bellón T, Blanca M. The innate immune system in delayed cutaneous allergic reactions to medications. Curr Opin Allergy Clin Immunol 2011; 11: 292-8.
68. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol 2006; 118: 949-56.
69. Rozières A, Vocanson M, Said B, Nosbaum A, Nicolas J-F. Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Clin Immunol 2009; 9: 305-10.
70. Sanderson J, Naisbitt D, Farrell J, et al. Sulfametoxazole and its metabolite nitroso-sulfametoxazole stimulate dendritic cell co-stimulatory signaling. J Immunol 2007; 178: 5533-42.
71. Elsheikh A, Lavergne S, Casterjon J, et al. Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism. J Immunol 2010; 185: 6448-60.
72. Chessman D, Kostenko L, Lethborg T, et al. Human Leukocyte antigen class-I restricted activation of CD8T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28: 822-32.
73. Pichler W. Pharmacological interactions of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2: 301-5.
74. Naisbitt D. Drug hypersensitivity reactions in the skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 2004; 15: 179-96.
75. Park B, Sanderson J, Naisbitt D. Drugs as haptens, antigens and immunogens. In: Pichler WJ, eds. Drug Hypersensitivity. Basel:Karger, 2007: 55-65.
76. Neves B, Cruz M, Francisco V, et al. Differential modulation of CXCR4 and CD40 protein levels by skin sensitizers and irritants in the FSCD cell line. Toxicology Letters 2008; 177: 74-82.
77. Imai S, Atarashi K, Ikesue K, Akiyama K, Tokura Y. Establishment of murine model of allergic photocontact dermatitis to ketoprofen and characterization of pathogenic T cells. J Dermatol Sci 2005; 41: 127-36.
78. Ariza A, Montañez M, Pérez-Sala D. Proteomics in immunological reactions to drugs. Curr Opin Allergy Clin Immunol 2011; 11: 305-12.
79. Gonçalo M, Figueiredo A, Tavares P, et al. Photosensitivity to piroxicam: absence of cross-reaction with tenoxicam. Contact Dermatitis 1992; 27: 287-90.
80. Gonçalo M. Explorations dans les photo-allergies médicamenteuses. In: GERDA. Progrès en Dermato-Allergologie. Nancy: John Libbey Eurotext, 1998: 67-74.
81. Gerber B, Pichler W. The p-i concept: evidence and implications. In:Pichler WJ, eds. Drug Hypersensitivity. Basel: Karger, 2007: 66-73.
82. Poszeczynska-Guigné E, Revuz J, Roujeau J. Mécanismes immunologiques des réactions cutanées aux médicaments. Ann Dermatol Venereol 2005; 132: 177-83.
83. Gonçalo M, Figueiredo A, Tavares P, et al. Photosensitivity to piroxicam: Absence of cross reaction with tenoxicam. Contact Dermatitis 1992; 27: 287-90.
84. Oliveira H, Gonçalo M, Reis J, Figueiredo A. Fixed drug eruption to piroxicam. Positive patch tests with cross-sensitivity to tenoxicam. J Dermatolog Treat 1999; 10: 209-12.
85. Pichler W, Beeler A, Keller M, et al. Pharmacological interaction of drugs with immune receptors: The p-i concept. Allergology International 2006; 55: 17-25.
86. Bellón T, Alavarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol 2010; 162: 1014-22.
87. Pérez A, Cabrerizo S, Barrio M, et al. Erythema-multiforme-like eruption from amoxycillin and allopurinol. Contact Dermatitis 2001; 44: 113-14.
88. Renn C, Straff W, DorfMüller A, et al. Amoxicillin-induced rash in young adults with infectious mononucleosis: demonstration of drug specific reactivity. Br J Dermatol 2002; 147: 1166-70.
89. Mardivirin L, Descamps V, Lacroix A, Delebassée S, Ranger-Rogez S. Eraly effects of drugs responsible for DRESS on HHV-6 replication in vitro. J Clin Virol 2009; 46: 300-2.
90. Gonçalo M. Phototoxic and photoallergic reactions. In: Johanssen J-D, Frosch P, Lepoitevin J-P, eds. Contact Dermatitis. 5th edn. Berlin-Heidelberg: Springer-Verlag, 2011: 361-76.
91. Lavergne S, Park B, Naisbitt D. The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol 2008; 8: 299-307.
92. Lan C, Wu C, Tsai P, Chen G. Diagnostic role of soluble Fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: a pilot study. Acta Derm Venereol 2006; 86: 215-18.
93. Chung W-H, Hung S, Hong H, et al. Medical genetics: a marker for Stevens-Johnson Syndrome. Nature 2004; 428: 426.
94. Hung S, Chung W-H, Chen Y. HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalized medicine. Pers Med 2005; 2: 225-37.
95. Aihara M. Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol 2011; 38: 246-54.
96. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-43.
97. Phillips E, Sullivan J, Knowles S, Shear N. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002; 16: 2223-5.
98. Phillips E, Mallal S. HLA and drug-induced toxicity. Curr Opin Mol Ther 2009; 11: 231-42.
99. Pellicano R, Lomuto M, Ciavarella G, Di Giorgio G, Gaasparini P. Fixed drug eruption with feprazone are linked to HLA-B22. J Am Acad Dermatol 1997; 36: 782-4.
100. Pichler W. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-93.
101. Zawodniak A, Lochmatter P, Yerly D, et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 2010; 65: 376-84.
102. Araujo E, Derissier V, Laprée G, et al. Death ligand TRAIL, secreted by CD1aand CD14cells in blister fluids, is involved in toxic epidermal necrolysis. Exp Dermatol 2011; 20: 107-12.
103. Chung W-H, Hung S, Yang J-Y, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nature Medicine 2008; 14: 1343-50.
104. Tapia B, Padial A, Sánchez-Sabaté E, et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004; 114: 335-40.
105. Tapia B, Martin-Diaz M, Díaz R, et al. Up-regulation of CCL17, CCL22 and CCR4 in drug-induced maculopapular exanthema. Clin Exp Allergy 2007; 37: 704-13.
106. Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Science Translational Medicine 2010; 2: 46ra62.
107. Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 1998; 139:1026-32.
108. Takahashi R, Kano Y, Yamazaki Y, et al. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182: 8071-9.
109. Wong G, Shear N. Is a drug alone sufficient to cause the drug hypersensitivity syndrome? Arch Dermatol 2004; 140: 226-30.
110. Speeckaert M, Speeckaert R, Lambert J, Brochez L. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol 2010; 20: 425-33.
111. Abe R. Toxic epidermal necrolysis and Stevens-Johnson syndrome:soluble Fas ligand involvement in the pathomechanisms of these diseases. J Dermatol Science 2008; 52: 151-159.
112. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004; 123: 850-5.
113. Azukizawa H. Animal models of toxic epidermal necrolysis. J Dermatol 2011; 38: 255-60.
114. Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8T cells and CD4T cells during the evolution of fixed drug eruption. Br J Dermatol 2008; 158: 1230-8.
115. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9: 316-21.
116. Choi H, Ku J, Kim M, et al. Possible role of Fas/Fas ligand mediated apoptosis in the pathogenesis of fixed drug eruption. Br J Dermatol 2006; 154: 419-25.
117. Teraki Y, Kokaji T, Shiohara T. Expansion of IL-10-producing CD4 and CD8T cells in fixed drug eruption. Dermatology 2003; 213:83-7.
118. Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption:the presence of CD25CD4T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology 2004; 209: 29-32.
119. Cravo M, Gonçalo M, Figueiredo A. Fixed drug eruption to cetrizine with positive lesional patch tests to the three piperazine derivatives. Int J Dermatol 2007; 46: 760-2